A pilot single-arm trial found that low-dose rapamycin increased cerebral blood flow and improved metabolic and inflammatory profiles in healthy middle-aged adults who carry the APOE4 gene allele.
Source: Human trial, no comparison group, 23 cognitively normal adults aged 45 to 65 years, including 9 APOE4 carriers and 14 non-carriers. Everyone in it got the treatment, so there is no group to compare with. Changes could come from other causes; this is early evidence.
What was found
Rapamycin significantly increased cerebral blood flow (CBF) in APOE4 carriers, with increases exceeding 15% across multiple brain regions. It also improved metabolic and inflammatory profiles in these participants, with minimal adverse effects.
Non-carriers showed no significant change in CBF and exhibited distinct physiological responses.
How it was done
Researchers conducted a single-arm trial of low-dose rapamycin (1 mg/day for 4 weeks) in cognitively normal adults aged 45 to 65 years. Participants were stratified by their APOE genotype.
The primary outcome measured was cerebral blood flow (CBF). Secondary outcomes included plasma metabolomics, inflammatory cytokines, Alzheimer's disease biomarkers, and gut microbiome composition.
What it does not show
This was a pilot single-arm trial, meaning it did not include a comparison group. The study involved a small number of participants and lasted for a short duration of 4 weeks.
Who was talking about it
- RTTNews on the news (2026-10-06): RTTNews reported on a study suggesting rapamycin may boost brain blood flow in people at higher Alzheimer's risk. See the post
The source
This is news, reported from the source above. It is not medical advice and not a recommendation. Talk to your doctor or pharmacist before you change any medicine or supplement.